Intra uterine drug delivery and its devolpment by Kailash Vilegave

Views:
 
     
 

Presentation Description

Development of IUDs Copper IUDs Hormone releasing IUDs

Comments

Presentation Transcript

SEMINAR ON:

SEMINAR ON INTRA UTERINE DRUG DELIVERY SYSTEM PTD BY : LAXMAN.S.VIJAPUR 1 ST M.PHARM PHARMACEUTICS

CONTENTS:

CONTENTS Development of IUDs Copper IUDs Hormone releasing IUDs

PowerPoint Presentation:

“Intra uterine devices are the object or piece of equipment that are designed to insert into the uterus for temporary contraception's” IUDs can be mainly classified as Non medicated Medicated

ANATOMY OF UTERUS:

ANATOMY OF UTERUS

Development of medicated IUDs:

Development of medicated IUDs Development of intrauterine contraceptive devices began in the 1920’s First their was development of IUDs with silk worm gut & flexible metal wire Then in mid 1930s their were several plastic IUDs of varying shape & sizes constructed Later a T-shaped IUDs were developed by Tatum

LOGICAL CONSIDERATION:

LOGICAL CONSIDERATION A logical consideration in the development of an IUD is that the device should confirm to the contours of the uterine cavity Considering some logics Tatum & Zipper tested for T-shaped copper IUD T-shape minimizes the distortion of myometrium & restricts the device from displacement & rotation by its 3 point contact

COPPER IUDs:

COPPER IUDs Zipper & his associates reported that copper ( and other metals such as zinc) bearing IUDs is most efficacious when copper wire is located on the transverse arm of the device, which is in close contact with the fundus

Biopharmaceutics of copper IUD:

Biopharmaceutics of copper IUD Copper appears to be released continuously from a copper bearing IUD b a combination of ionization & chelation processes The mean diameter of the copper wire was observed to reduce with time due to corrosion & flaking of the metal Analysis of 284 Cu-7 IUD inserted intrauterinally in women for up to 40 months showed release of copper at a daily dose of 9.87 μ gm/day

PowerPoint Presentation:

The linear relationship between the cumulative amount of copper released intrauterinally with the duration IUD in residence IUD insertion in months Cumulative drug released

FACTORS EFFECTING COPPER IUDs ANTIFERTILLITY ACTIVITY:

FACTORS EFFECTING COPPER IUDs ANTIFERTILLITY ACTIVITY Uptake of copper Calcium deposition & protein coating Surface area of contraceptive wire ie:copper

Development of hormone releasing IUD:

Development of hormone releasing IUD Hormone releasing IUDs was first initiated by Doyle & Clewe This development took due to inactivation of progesterone orally Development was initiated with silicone capsules to a modified Lippes loop Results showed their were histological changes in the endometrium which lead to interference in normal reproductive system Further development lead to development of T-shaped Progesterone releasing IUDs

PowerPoint Presentation:

Pharris developed a new version of progesterone releasing IUD In 1975 US FDA gave approval as medicated IUD for 12-month intrauterine contraception Release of drug was found to be 65 μ gm/ml Polyethylene Ethylene vinyl acetate copolymer 38 mg of progesterone microcrystal suspended in silicone oil

HARMONRE RELEASING IUDs:

HARMONRE RELEASING IUDs A) Membrane controlled reservoir type 1) Single component system 2) Multi component system B) Polymer matrix controlled DDS 1) Retrievable matrix device 2) Biodegradable matrix device C) Sandwich type DDS

Sandwich type IUD:

Sandwich type IUD This type of IUD is a hybrid of a polymer membrane permeation-controlled delivery system with a polymer matrix diffusion-controlled DDS Ex: Levonorgestrel by Leiras Pharmaceuticals Nova-T polyethylene Polydimethyl siloxane 60 mg of levonorgestrel dispersed in Polydimethyl siloxane

Biopharmaceutics of intrauterine progesterone administration:

Biopharmaceutics of intrauterine progesterone administration The uterine bioavailability & tissue distribution of progesterone following intrauterine administration were compared with that attained by oral delivery & Subcutaneous injection as shown in the fig Intraluminal instillation Oral delivery Hours after administration Log (uterine radioactivity conc)

Clinical significance of progesterone:

Clinical significance of progesterone 1 year placebo study:- 22% pregnancy 10 μ gm/ml progesterone :- 5.2% 25 μ gm/ml progesterone:- 2.7% 65 μ gm/ml progesterone :-1.1% 120 μ gm/ml progesterone :- 0.6%

REFRENCES:

REFRENCES Novel drug delivery systems by Yie.W.Chein Controlled & Novel drug delivery by N.K.Jain Controlled drug delivery system by Joseph.R.Robinson

authorStream Live Help